Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.53 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.52 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.52 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.52 |
| ▸ | CCR5 known ✓ | P51681 | 1/20 | 0.52 |
| ▸ | PDGFRB known ✓ | P09619 | 1/20 | 0.52 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 7/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.66 |
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30614510 | 0.98 | MEN1 (0.68) | MEN1KMT2ARAB9ALMNASMN1; SMN2 | |
| SCHEMBL170428 | 0.98 | MEN1 (0.68) | MEN1KMT2ARAB9ALMNASMN1; SMN2 | |
| Water SCHEMBL10865815 | 0.96 | MEN1 (0.66) | MEN1KMT2ARAB9ALMNASMN1; SMN2 | |
| Ethane SCHEMBL27458330 | 0.96 | MEN1 (0.66) | MEN1KMT2ARAB9ALMNASMN1; SMN2 | |
| SCHEMBL28259240 | 0.89 | MEN1 (0.59) | MEN1KMT2ARAB9ALMNASMN1; SMN2 | |
| Acetic Acid SCHEMBL8159401 | 0.88 | PDE10A (0.60) | MEN1KMT2ARAB9ALMNASMN1; SMN2 | |
| Toluene SCHEMBL27569075 | 0.88 | LMNA (0.57) | MEN1KMT2ARAB9ALMNASMN1; SMN2 | |
| SCHEMBL27453447 | 0.88 | RAB9A (0.61) | MEN1KMT2ARAB9ALMNASMN1; SMN2 | |
| SCHEMBL8928619 | 0.85 | MEN1 (0.54) | MEN1KMT2ARAB9ALMNASMN1; SMN2 | |
| SCHEMBL12926855 | 0.83 | PDE10A (0.59) | MEN1KMT2ARAB9ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0445731-B1 | Azabicyclo and azacyclo oxime and amine cholinergic agents and pharmaceutically acceptable salts thereof | WARNER LAMBERT CO (US) | 1996-01-10 | — | — | EP | claimed |
| EP-0445731-A1 | Azabicyclo and azacyclo oxime and amine cholinergic agents and pharmaceutically acceptable salts thereof | WARNER-LAMBERT COMPANY (US) | 1991-09-11 | — | — | EP | claimed |
| EP-2651895-B1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2015-07-01 | — | — | EP | disclosed |
| CN-103249720-B | Oxime compounds as HDL-holesterol raising agents | HOFFMANN LA ROCHE | 2015-05-20 | — | — | CN | disclosed |
| US-8669254-B2 | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents | HOFFMAN-LA ROCHE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| EP-2651895-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| CN-103249720-A | Oxime compounds as HDL-holesterol raising agents | HOFFMANN LA ROCHE | 2013-08-14 | — | — | CN | disclosed |
| WO-2012080144-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| US-20120157476-A1 | OXIME COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20050059662-A1 | Substituted quinazolinone compounds | CHIRON CORPORATION | 2005-03-17 | — | — | US | disclosed |
| CN-1156446-C | Indenoindolone compounds, their preparation and medicinal compositions containing them | ɪά��ʵ���� | 2004-07-07 | — | — | CN | disclosed |
| WO-1993008191-A1 | AZABICYCLO OXIME AND AMINE CHOLINERGIC AGENTS AND METHODS OF TREATMENT | WARNER-LAMBERT COMPANY (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0271798-B1 | O-SUBSTITUTED TETRAHYDROPYRIDINE OXIME CHOLINERGIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1993-04-07 | — | — | EP | disclosed |
| US-5110828-A | Treatment or prophylaxis of dementia | BEECHAM GROUP P.L.C. (GB) | 1992-05-05 | — | — | US | disclosed |
| EP-0445731-A1 | Azabicyclo and azacyclo oxime and amine cholinergic agents and pharmaceutically acceptable salts thereof | WARNER-LAMBERT COMPANY (US) | 1991-09-11 | — | — | EP | disclosed |
| EP-0338723-A1 | Novel compounds | BEECHAM GROUP PLC (GB) | 1989-10-25 | — | — | EP | disclosed |
| CN-1035663-A | The preparation method of the quinoline that replaces | SMITHKLINE BECKMAN INTERCREDIT (NL) | 1989-09-20 | — | — | CN | disclosed |
| CN-1033380-A | Compound | SMITHKLINE BECKMAN INTERCREDIT (NL) | 1989-06-14 | — | — | CN | disclosed |
| US-4786648-A | ANALGESIC | WARNER-LAMBERT COMPANY (US) | 1988-11-22 | — | — | US | disclosed |
| EP-0271798-A2 | O-Substituted tetrahydropyridine oxime cholinergic agents | WARNER-LAMBERT COMPANY (US) | 1988-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059662-A1 | Substituted quinazolinone compounds | MC4R, MC2R, MC3R | GAA 2324/4885HSP90AA1 2983/4885MMP8 2948/4885 |
| US-20120157476-A1 | OXIME COMPOUNDS | APOB, APOL1, PON1 | GAA 919/4885HSP90AA1 2507/4885MMP8 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.